nCounter®
PanCancer Progression Panel
Helping Your Research
Cancer progression involves multiple processes and mechanisms that are highly interconnected. The nCounter PanCancer Progression Panel lets you perform multiplex gene expression analysis with 770 genes from each step in the cancer progression process including: angiogenesis, extracellular matrix remodeling (ECM), epithelial-to-mesenchymal transition (EMT) and metastasis.
- Comprehensive gene expression analysis of cancer progression
- Quantify gene expression of metastatic growth and suppressor genes
- Rapidly and easily screen samples for biomarker discovery or drug mechanism of action to support your research
- Customizable with up to 55 additional user-defined genes with Panel Plus option
- 3D-enabled for multi-analyte analysis with Vantage 3D™ Assays
Inspired by systems biology approaches to cancer research, NanoString’s 360 Series Panel Collection gives you a 360° view of gene expression by combining carefully-curated content involved in the biology of the tumor, microenvironment, and the immune response into a single holistic assay. Each panel contains the 18-gene Tumor Inflammation Signature (TIS) that measures a peripherally-suppressed, adaptive immune response and has been shown to correlate with response to checkpoint inhibitors.
How It Works
Progression Panel Gene Coverage
The following is a pictorial description of the processes and key genes included in the PanCancer Progression Panel
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
360 Series Product Comparison
Fully-annotated gene lists in Excel format are available for each of the 360 Panels. The table below compares the biology coverage of the 360 Panels across the tumor, microenvironment, and the immune response to that of the PanCancer Panels Collection.
Publications
Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer
Background: Most renal cell carcinomas (RCCs) are localized and managed by active surveillance, surgery, or minimally invasive techniques. Stereotactic ablative radiation (SAbR) may provide an innovative non-invasive alternative although prospective data are limited.
MULTIPLATFORM ANALYSIS OF INTRATUMORAL PTEN HETEROGENEITY IN MELANOMA
Loss of protein expression of the tumor suppressor PTEN is associated with increased cancer aggressiveness, decreased tumor immune infiltration, and resistance to immune and targeted therapies in melanoma. We assessed a unique cohort of 8 melanoma samples with focal loss of PTEN protein expression to understand features and mechanisms of PTEN loss in this disease.
Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
Background: Immunotherapy for malignant tumors has made great progress, but many patients do not benefit from it. The complex intratumoral heterogeneity (ITH) hindered the in-depth exploration of immunotherapy.
Request a Quote
Contact our helpful experts and we’ll be in touch soon.
